Bosh sahifaEVGN • NASDAQ
add
Evogene Ltd
Yopilish kursi
1,57 $
Kunlik diapazon
1,45 $ - 1,57 $
Yillik diapazon
1,20 $ - 10,40 $
Bozor kapitalizatsiyasi
8,32 mln USD
Oʻrtacha hajm
66,81 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 1,80 mln | -52,32% |
Joriy xarajat | 8,17 mln | 9,83% |
Sof foyda | -7,63 mln | -91,52% |
Sof foyda marjasi | -424,83 | -301,69% |
Har bir ulushga tushum | -1,31 | -63,75% |
EBITDA | -6,83 mln | -93,87% |
Amaldagi soliq stavkasi | -0,01% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 19,95 mln | -46,40% |
Jami aktivlari | 40,11 mln | -30,53% |
Jami passivlari | 27,88 mln | 27,39% |
Umumiy kapital | 12,24 mln | — |
Tarqatilgan aksiyalar | 6,79 mln | — |
Narxi/balansdagi bahosi | -2,45 | — |
Aktivlardan daromad | -45,97% | — |
Kapitaldan daromad | -110,69% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -7,63 mln | -91,52% |
Operatsiyalardan naqd pul | -4,93 mln | -14,15% |
Sarmoyadan naqd pul | 2,02 mln | -44,68% |
Moliyadan naqd pul | 4,73 mln | -39,30% |
Naqd pulning sof oʻzgarishi | 1,83 mln | -74,18% |
Boʻsh pul | 1,24 mln | 140,67% |
Haqida
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
CEO
Tashkil etilgan
2002
Sayt
Xodimlar soni
142